Suppr超能文献

使用阿米替林治疗的疼痛性神经病变患者中禁忌的医疗状况及禁用药物的患病率

Prevalence of contraindicated medical conditions and use of precluded medications in patients with painful neuropathic disorders prescribed amitriptyline.

作者信息

Gore Mugdha, Dukes Ellen, Rowbotham David, Tai Kei-Sing, Leslie Douglas L

机构信息

Avalon Health Solutions, Inc., Philadelphia, Pennsylvania 19102, USA.

出版信息

Pain Pract. 2006 Dec;6(4):265-72. doi: 10.1111/j.1533-2500.2006.00101.x.

Abstract

Amitriptyline is a tricyclic antidepressant that is historically indicated and used to manage depression. More recently, due to clinical evidence demonstrating efficacy, it is often prescribed in the management of painful neuropathic disorders (PNDs). However, the amitriptyline label contains numerous preclusions (contraindications, warnings/precautions, drug interactions). Our objective was to measure the frequency of amitriptyline prescriptions in PND patients using the U.K. General Practice Research Database and assess whether any prescriptions were given to patients with preclusions listed in the product label. We identified a total of 13,546 patients (mean age 59 +/- 16.2 years; 66.7% female) who had a diagnosis of a PND and received > or =1 prescription for amitriptyline between July 1998 and June 2001. Nearly half (46.7%) of PND patients prescribed amitriptyline had > or =1 preclusion for its use; 3.5% had > or =1 contraindication; 22% had > or =1 warning/precaution; and 33% received > or =1 medication with a potential for drug interactions with amitriptyline. Preclusions were more likely in women than in men (48.3% vs. 43.4%, P < 0.0001); their incidence increased with age (42.8%, 50.4%, 55.1%, and 52.3% among those ages <65, 65-74, 75-84, and 85+ years, P < 0.0001), and the number of patients with preclusions was the highest in the phantom limb pain group (67.4%) and lowest in the atypical facial pain group (42.9%), P < 0.001. The average daily amitriptyline doses (starting: 33.6 +/- 32.4 mg; maintenance: 42.1 +/- 39.9 mg) were low compared to those used for the treatment of depression. Results indicate that, in a significant number of cases, the existence of preclusions did not prevent the prescribing of amitriptyline. Our findings raise a potential concern about the way this medication is being used. However, the clinical significance of these data is, as yet, unclear. Although, in theory, adverse outcomes may have been associated with this practice, we could not confirm this with this database analysis.

摘要

阿米替林是一种三环类抗抑郁药,历来用于治疗抑郁症。最近,由于临床证据表明其有效性,它常用于治疗疼痛性神经病变(PND)。然而,阿米替林的药品说明书包含许多限制条件(禁忌症、警告/注意事项、药物相互作用)。我们的目的是使用英国全科医学研究数据库来衡量PND患者中阿米替林处方的频率,并评估是否有任何处方是开给药品说明书中列出有限制条件的患者。我们共识别出13546名患者(平均年龄59±16.2岁;66.7%为女性),他们被诊断患有PND,并且在1998年7月至2001年6月期间接受了≥1次阿米替林处方。在开具阿米替林处方的PND患者中,近一半(46.7%)有≥1项使用该药的限制条件;3.5%有≥1项禁忌症;22%有≥1项警告/注意事项;33%接受了≥1种可能与阿米替林发生药物相互作用的药物。女性的限制条件比男性更常见(48.3%对43.4%,P<0.0001);其发生率随年龄增加(年龄<65岁、65 - 74岁、75 - 84岁和85岁以上者中分别为42.8%、50.4%、55.1%和52.3%,P<0.0001),且限制条件患者数量在幻肢痛组中最高(67.4%),在非典型面部疼痛组中最低(42.9%),P<0.001。与用于治疗抑郁症的剂量相比,阿米替林的平均日剂量(起始剂量:33.6±32.4毫克;维持剂量:42.1±39.9毫克)较低。结果表明,在相当多的病例中,存在限制条件并未阻止阿米替林的处方开具。我们的研究结果引发了对这种药物使用方式的潜在担忧。然而,这些数据的临床意义目前尚不清楚。虽然从理论上讲,这种做法可能与不良后果相关,但我们无法通过该数据库分析来证实这一点。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验